Organon: Poor Q3 Earnings Make Bear Case (NYSE:OGN)


Money on the edge

PM Images

Investment Overview

Organon & Co. (NYSE:OGN), formed via Pharma giant Merck & Co.’s (MRK) spinout of its Established Brands, Women’s Health and Biosimilars divisions, announced its Q3 earnings on Thursday, November 2.

I covered Organon’s Q2 earnings in



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *